Form D · Biotechnology

AMGEN INC

Thousand Oaks, CA · CIK 0000318154

Offering snapshot reported Jan 23, 2015 · SEC filing

Reported sold
$0
Offering amount: $2.5B
Investors reported
34
Form D · investor count
Minimum accepted
$250K
Reported outside-investor minimum
First sale
Sep 28, 2011
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$0.5$1Mar 14, 2011Feb 29, 2012: $0.00Feb 29, 2012Feb 4, 2013: $0.00Feb 4, 2013Jan 29, 2014: $0.00Jan 29, 2014Jan 23, 2015: $0.00Jan 23, 2015

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported investors0 → 34

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 23, 2015Amendment$0No comparison34SEC filing
Jan 29, 2014Amendment$0No comparison34SEC filing
Feb 4, 2013Amendment$0No comparison34SEC filing
Feb 29, 2012Amendment$0No comparison34SEC filing
Mar 14, 2011InitialYet to sellNo comparison0SEC filing
May 23, 2008PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Other
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$750K (estimated)
Finders' fees
$0
Form D file number
021-156628
This is a continuous commercial paper program. The total amount offered represents the maximum authorized amount. As of the date of this filing, no amounts are outstanding under this program.
Commercial Paper
Annualized estimate based on the total offering amount of the program.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Goldman, Sachs & Co.361
Barclays Capital Inc.19714N/A
Citigroup Global Markets Inc.7059N/A
Banc of America Securities LLC26091
Morgan Stanley & Co. Incorporated8209
Deutsche Bank Securities Inc.2525

Source: Form D, filed Jan 23, 2015. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Madhavan Balachandran Executive
David Baltimore Director
David W Beier Executive
Frank J. Biondi, Jr. Director
Fabrizio Bonanni Executive
Robert A. Bradway Director, Executive
Jerry D Choate Director
Vance D. Coffman Director
Francois De Carbonnel Director
Thomas J.W. Dittrich Executive
Robert A. Eckert Director
Greg C. Garland Director
Frederick W Gluck Director
Sean E. Harper Executive
Rebecca M. Henderson Director
Frank C. Herringer Director
Anthony C. Hooper Executive
Tyler Jacks Director
Michael A. Kelly Executive
Brian M. Mc Namee Executive
David W. Meline Executive
Gilbert S. Omenn Director
Cynthia M. Patton Executive
Jonathan Peacock Executive
Judith C. Pelham Director
Roger M Perlmutter Executive
David Piacquad Executive
J. Paul Reason Director
J Paul Reason Director
Anna S Richo Executive
Leonard D. Schaeffer Director
David J. Scott Executive
Kevin W Sharer Director, Executive
Ronald D. Sugar Director
Scott A. Tross Executive
Stuart A. Tross Executive
R. Sanders Williams Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
One Amgen Center Drive
Thousand Oaks, CA, 91320